The government has proposed extending the compliance deadline for revised Schedule M norms for pharmaceutical manufacturing.

Drugmakers in India may soon face stricter enforcement of quality standards. The revised Schedule M, which details ...

It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.

Did you know that back in the 1980s and '90s, when South Korea was on the road toward becoming—but had yet to become—the ...

Indian pharma notes revised Schedule M extension signals key step to avoid closure of units: Nandita Vijayasimha, Bengaluru Tuesday, January 7, 2025, 08:00 Hrs [IST] Indian pharma ...

It specifies that by 2035, China expects to fully ensure the safety, efficacy and accessibility of drugs and medical devices, ...

The expectations for the reduction of drug prices by stakeholders in the pharmaceutical sector have been dashed following the ...

In a warning letter posted online late last month, the FDA scolded Viatris over a range of production slights at the ...

Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance maintained that the Indian pharmaceutical industry is at a ...

India’s revised Schedule M norms for pharmaceutical manufacturing, effective January 1, require compliance with stricter ...

Kazakhstan’s healthcare system underwent significant reforms to improve accessibility, efficiency and transparency. In an ...

How India’s healthcare sector is accelerating towards Viksit Bharat 2047 As India aims to achieve its ambitious goal of ...